Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 2 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Drug common name | IMARADENANT |
INN | imaradenant |
Description | Imaradenant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target adenosine receptor A2b, adenosine receptor A1, and adenosine receptor A2a. |
Classification | Small molecule |
Drug class | adenosine receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(-c2nnc(N)nc2-c2ccc(F)cc2)cc(Cl)n1 |
PDB | — |
CAS-ID | 1321514-06-0 |
RxCUI | — |
ChEMBL ID | CHEMBL4594442 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 770140J08A (ChemIDplus, GSRS) |